Anne-Kathrin Trampe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anne-Kathrin Trampe has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A. Chan
From the Department of Neurology (A.K.T., A.S., A.H., K.H., R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Institut für Medizinische Biometrie und Statistik (C.H., A.Z.), Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany; Clinic for Neurology-Inflammatory Disorders of the Central Nervous System and Neurooncology (H.W.), University of Münster, Münster, Germany; and Elan Pharmaceuticals (S.G.), Dublin, Ireland
1 shared publicationA. Haghikia
From the Department of Neurology (A.K.T., A.S., A.H., K.H., R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Institut für Medizinische Biometrie und Statistik (C.H., A.Z.), Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany; Clinic for Neurology-Inflammatory Disorders of the Central Nervous System and Neurooncology (H.W.), University of Münster, Münster, Germany; and Elan Pharmaceuticals (S.G.), Dublin, Ireland
1 shared publicationA. Stroet
From the Department of Neurology (A.K.T., A.S., A.H., K.H., R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Institut für Medizinische Biometrie und Statistik (C.H., A.Z.), Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany; Clinic for Neurology-Inflammatory Disorders of the Central Nervous System and Neurooncology (H.W.), University of Münster, Münster, Germany; and Elan Pharmaceuticals (S.G.), Dublin, Ireland
1 shared publication- Ala Ahrari
Department of Neuroanatomy and Molecular Brain Research, Institute of Anatomy, Ruhr University Bochum, 44801 Bochum, Germany
1 shared publication - Andreas Ziegler
Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication C. Hemmelmann
From the Department of Neurology (A.K.T., A.S., A.H., K.H., R.G., A.C.), St. Josef Hospital, Ruhr University, Bochum, Germany; Institut für Medizinische Biometrie und Statistik (C.H., A.Z.), Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany; Clinic for Neurology-Inflammatory Disorders of the Central Nervous System and Neurooncology (H.W.), University of Münster, Münster, Germany; and Elan Pharmaceuticals (S.G.), Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 28 November 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (12) , 1662
Early Postnatally Induced Conditional Reelin Deficiency Causes Malformations of Hippocampal Neurons
The extracellular matrix protein reelin is well known for orchestrating radial migration of cortical neurons during embryonic cortical development. While in the reeler mutant mouse, lacking reelin expression, radially migrating neurons are malpositioned and display dendritic malformations, no such deficits were found after conditionally induced reelin deficiency (RelncKO) in the hippocampus of mice aged two months. Here, we addressed the question whether or not RelncKO, when induced early after birth, might cause malformations of hippocampal neurons. For instance, we could recently show dendritic hypertrophy of somatosensory and entorhinal cortex neurons after early induced RelncKO. In the present study, reelin deficiency in RelncKO mice was induced immediately after birth, and the analysis of reconstructed Golgi-stained hippocampal neurons from these mice, when aged 4 weeks, revealed morphological malformations. Dentate granule cells were the most affected from all analyzed hippocampal neuronal cell types. Thus, RelncKO granule cells had a significantly smaller soma size and displayed atrophy of proximal dendritic segments when compared to wild type (wt). Malformations of interneurons were only subtle and cell type specific; thus, multipolar but not bitufted interneurons developed proximal dendritic hypertrophy. Also, the dendrite morphology of CA2- and CA3-pyramidal cells was affected, while we did not detect morphological changes of CA1-pyramidal cell dendrites. In summary, our results show that early postnatal RelncKO causes morphological malformations of hippocampal neurons, in particular of dentate granule cells. Taken together with our previous findings, we conclude that not only specific types of entorhinal- and neocortical neurons, but also types of hippocampal neurons are at risk of developing malformations if reelin expression is reduced during a critical early postnatal period.
- 28 November 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (12) , 1662
Open AccessEarly Postnatally Induced Conditional Reelin Deficiency Causes Malformations of Hippocampal Neurons
The extracellular matrix protein reelin is well known for orchestrating radial migration of cortical neurons during embryonic cortical development. While in the reeler mutant mouse, lacking reelin expression, radially migrating neurons are malpositioned and display dendritic malformations, no such deficits were found after conditionally induced reelin deficiency (RelncKO) in the hippocampus of mice aged two months. Here, we addressed the question whether or not RelncKO, when induced early after birth, might cause malformations of hippocampal neurons. For instance, we could recently show dendritic hypertrophy of somatosensory and entorhinal cortex neurons after early induced RelncKO. In the present study, reelin deficiency in RelncKO mice was induced immediately after birth, and the analysis of reconstructed Golgi-stained hippocampal neurons from these mice, when aged 4 weeks, revealed morphological malformations. Dentate granule cells were the most affected from all analyzed hippocampal neuronal cell types. Thus, RelncKO granule cells had a significantly smaller soma size and displayed atrophy of proximal dendritic segments when compared to wild type (wt). Malformations of interneurons were only subtle and cell type specific; thus, multipolar but not bitufted interneurons developed proximal dendritic hypertrophy. Also, the dendrite morphology of CA2- and CA3-pyramidal cells was affected, while we did not detect morphological changes of CA1-pyramidal cell dendrites. In summary, our results show that early postnatal RelncKO causes morphological malformations of hippocampal neurons, in particular of dentate granule cells. Taken together with our previous findings, we conclude that not only specific types of entorhinal- and neocortical neurons, but also types of hippocampal neurons are at risk of developing malformations if reelin expression is reduced during a critical early postnatal period.
- 29 May 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (22) , 1736-1742
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
Objective: To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: This was a blinded, retrospective cross-sectional and longitudinal analysis for anti-JCV antibodies using a confirmatory 2-step ELISA on 2,782 blood samples obtained from 2,253 patients nationwide for routine testing for anti-natalizumab antibodies during open-label treatment between 2007 and 2010. Results: Of the natalizumab-treated patients with MS, 58.8% tested positive for anti-JCV antibodies. The rate of seropositivity was higher in males and increased with age, with a plateau between age intervals 20–29 and 30–39 years. In longitudinal analyses, 19 of 194 (9.8%) patients converted from anti-JCV antibody-negative to seropositive status over 7.7 months; 4.7% reverted from antibody-positive to seronegative status over 7.9 months. Antibody levels, especially in the latter group, were low, indicating fluctuations around the lower cut point of the assay. Neither anti-JCV serostatus nor antibody levels were associated with immunosuppressive pretreatment, duration of natalizumab treatment, or anti-natalizumab antibodies. All samples obtained from 10 patients who developed PML were seropositive (13 samples before PML diagnosis [2.0–37.6 months]; 2 samples at diagnosis). Antibody levels in these samples were higher than those in samples from seropositive patients who did not develop PML. Conclusions: These data argue for the potential clinical utility of JCV serology for PML risk stratification. However, further investigations of fluctuations in serostatus and of antibody levels for a more precise understanding of the predictive value are warranted.
- 29 May 2012
- Published by Wolters Kluwer Health in Neurology
- Vol. 78 (22) , 1736-1742
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort
Objective: To investigate the rate of seropositivity of anti-JC virus (JCV) antibodies in a German multiple sclerosis (MS) cohort treated with natalizumab in the postmarketing setting and to assess anti-JCV serostatus in samples obtained before diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: This was a blinded, retrospective cross-sectional and longitudinal analysis for anti-JCV antibodies using a confirmatory 2-step ELISA on 2,782 blood samples obtained from 2,253 patients nationwide for routine testing for anti-natalizumab antibodies during open-label treatment between 2007 and 2010. Results: Of the natalizumab-treated patients with MS, 58.8% tested positive for anti-JCV antibodies. The rate of seropositivity was higher in males and increased with age, with a plateau between age intervals 20–29 and 30–39 years. In longitudinal analyses, 19 of 194 (9.8%) patients converted from anti-JCV antibody-negative to seropositive status over 7.7 months; 4.7% reverted from antibody-positive to seronegative status over 7.9 months. Antibody levels, especially in the latter group, were low, indicating fluctuations around the lower cut point of the assay. Neither anti-JCV serostatus nor antibody levels were associated with immunosuppressive pretreatment, duration of natalizumab treatment, or anti-natalizumab antibodies. All samples obtained from 10 patients who developed PML were seropositive (13 samples before PML diagnosis [2.0–37.6 months]; 2 samples at diagnosis). Antibody levels in these samples were higher than those in samples from seropositive patients who did not develop PML. Conclusions: These data argue for the potential clinical utility of JCV serology for PML risk stratification. However, further investigations of fluctuations in serostatus and of antibody levels for a more precise understanding of the predictive value are warranted.